Phase 3 results for the Novartis malaria drug “GanLum” show it was comparable to the standard of care and led to cure rates that top the threshold recommended by the World Health Organization. If approved, this new combination drug would become the first novel malaria therapy in more than 25 years.
The post Novel Novartis Malaria Drug Shows Promise to Become New Asset Against Resistant Strains appeared first on MedCity News.
Biosimilars: a vital remedy for Europe’s healthcare challenges
Discover how biosimilars in Europe expand access, cut costs, and strengthen healthcare systems for a more sustainable future. The post Biosimilars: a vital remedy for
